StreetInsider.com News Articles

Form 8-K Liminatus Pharma, Inc. For: Jul 29

Thu, 30 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260730/26837893.html

Form 8-K Liminatus Pharma, Inc. For: Jul 29

Thu, 30 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260730/26837893.html

Form 8-K Liminatus Pharma, Inc. For: Jul 20

Fri, 24 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260724/26814127.html

Form 8-K Liminatus Pharma, Inc. For: Jul 20

Fri, 24 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260724/26814127.html

Form SCHEDULE 13G Liminatus Pharma, Inc. Filed by: Samda Biolab Co., Ltd.

Wed, 22 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260722/26802598.html

Form SCHEDULE 13G Liminatus Pharma, Inc. Filed by: Samda Biolab Co., Ltd.

Wed, 22 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260722/26802598.html

Form 4 Liminatus Pharma, Inc. For: Jul 02 Filed by: Kim Chris

Tue, 14 Jul 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260714/26769228.html

Form 4 Liminatus Pharma, Inc. For: Jul 02 Filed by: Kim Chris

Tue, 14 Jul 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260714/26769228.html

Form SCHEDULE 13D/A Liminatus Pharma, Inc. Filed by: Valetudo Therapeutics LLC

Tue, 14 Jul 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260714/26769208.html

Form SCHEDULE 13D/A Liminatus Pharma, Inc. Filed by: Valetudo Therapeutics LLC

Tue, 14 Jul 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260714/26769208.html

Form DEF 14A Liminatus Pharma, Inc. For: Aug 03

Mon, 13 Jul 2026 08:44:00 -0400

si-local-file:///var/storage/secattach/20260713/26760393.html

Form DEF 14A Liminatus Pharma, Inc. For: Aug 03

Mon, 13 Jul 2026 08:44:00 -0400

si-local-file:///var/storage/secattach/20260713/26760393.html

Form 4 Liminatus Pharma, Inc. For: Jun 24 Filed by: Kim Chris

Mon, 06 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260706/26736390.html

Form 4 Liminatus Pharma, Inc. For: Jun 24 Filed by: Kim Chris

Mon, 06 Jul 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260706/26736390.html

Form 3 Liminatus Pharma, Inc. For: Jun 24 Filed by: Ewon Comfortech Co., Ltd.

Mon, 06 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260706/26736375.html

Form 3 Liminatus Pharma, Inc. For: Jun 24 Filed by: Ewon Comfortech Co., Ltd.

Mon, 06 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260706/26736375.html

Form SCHEDULE 13G/A Liminatus Pharma, Inc. Filed by: Ewon Comfortech Co., Ltd.

Mon, 06 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260706/26736367.html

Form SCHEDULE 13G/A Liminatus Pharma, Inc. Filed by: Ewon Comfortech Co., Ltd.

Mon, 06 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260706/26736367.html

Form 8-K Liminatus Pharma, Inc. For: Jun 29

Mon, 06 Jul 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260706/26733534.html

Form 8-K Liminatus Pharma, Inc. For: Jun 29

Mon, 06 Jul 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260706/26733534.html

Liminatus Pharma amends merger deal with InnocsAI, closing set July 2

Tue, 30 Jun 2026 16:30:13 -0400

Liminatus Pharma, Inc. (Nasdaq: LIMN) has amended its definitive merger agreement with InnocsAI LLC, restructuring the transaction to allow closing before obtaining stockholder approval, according to a press release from the company.

The closing is now expected to occur on July 2, 2026, subject to customary closing conditions. The deal carries an aggregate implied transaction value of approximately $320 million.

Under the amended terms, InnocsAI equity holders will receive a combination of Liminatus common stock and newly designated non-voting convertible preferred stock, priced at $0.20 per common share. Equity holders will also receive contingent value rights entitling them to 20% of future

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

Tue, 30 Jun 2026 16:30:00 -0400

Transaction Expected to Close July 2, 2026

FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology company focused on next-generation cell therapy technologies.

The transaction has been re-structured to allow closing prior to obtaining stockholder approval, with closing now expected to occur on July 2, 2026, subject to the satisfaction or waiver of customary closing conditions.

Under the amended terms of